Fig. 7: Systematic antitumor immune responses mechanism in 4T1-bearing mice.

a Schematic illustration of experimental design. b Quantitation of the percent of mature DCs (CD11c⁺CD80⁺CD86⁺) (**p = 0.0048, ***p = 0.0001, **p = 0.0046) in tumor-draining lymph nodes on day 2 after various treatment (1: PBS (+); 2: free Oxa; 3: Oxa(IV)@ZnPc; 4: Oxa(IV)@ZnPc@M; 5: BMMs + anti-PD-L1; 6: Oxa(IV)@ZnPc (+); 7: Oxa(IV)@ZnPc@M (+); 8: Oxa(IV)@ZnPc@M (+) + anti-PD-L1, “(+)” represent with laser irradiation, applied for all the studies in vivo). c The representative flow cytometric plots of tumor-infiltrating CD4⁺ T cells and CD8⁺ T cells. Quantitation of the percent of tumor-infiltrating d CD4⁺T cells (**p = 0.0060, ***p = 0.0002, *p = 0.0102) and e CD8⁺T cell in tumors analyzed on day 6 after various treatment (**p = 0.0047, **p = 0.0038, **p = 0.0098). f The representative flow cytometric plots of IFN-γ within CD8⁺ T cells. Quantitation of the percent of g IFN-γ within CD8⁺ T cells (***p = 0.0005, ***p < 0.0001) and h TNF-α within CD8⁺ T cells in tumors analyzed on day 6 after various treatment (**p = 0.0047, ***p = 0.0001, **p = 0.0030). Quantitation of the percent of i intratumoral ratio of CD8⁺ T cells to Treg (**p = 0.0096, ***p = 0.0009, **p = 0.0078) and j CD4⁺ T cells to Treg (*p = 0.0340, **p = 0.0040). All data were presented as mean ± SD (n = 4 individual animals). Statistical significance was calculated via ordinary one-way ANOVA with a Tukey’s test b or Dunnett’s test d, e and g–j. *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source data file.